Tag Archives: HCW

HCW Announces Written Notice from NASDAQ

HCW Announces Written Notice from NASDAQ

HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported on December 17, 2024, the Company received written notice from the Listing Qualifications Staff that it had failed to re-gain compliance for continued listing requirements of the NASDAQ …

Read More »